Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Genotype-guided Clear all
Recruiting No phase listed Observational

Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke

NCT06292117
View directory record Official record
Conditions
Ischemic Stroke, CYP2C19 Polymorphism
Interventions
CYP2C19 Genotype
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

NCT00927862
View directory record Official record
Conditions
Thromboembolism
Interventions
IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
Genetic · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 24, 2026, 4:58 PM EDT
Terminated No phase listed Observational Results available

Pharmacogenomics for Antidepressant Guidance and Education

NCT01555021
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Genotyping assays
Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain

NCT03637998
View directory record Official record
Conditions
Chronic Low Back Pain, Self-Management
Interventions
Problem-solving Pain to Enhance Living Well (PROPEL)
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

NCT02566057
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders, Bipolar Disorder
Interventions
PGx testing guided treatment (PGT)
Biological
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Clinical and Economic Implications of Genetic Testing for Warfarin Management

NCT00964353
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
Warfarin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients

NCT01183494
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFIRI, Avastin, Irinotecan
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 24, 2026, 4:58 PM EDT
Terminated Not applicable Interventional

Thrombocyte Activity Reassessment and GEnoTyping for PCI(TARGET-PCI)

NCT01177592
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
VerifyNow, Verigene
Device
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional

A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression

NCT02189057
View directory record Official record
Conditions
Depression, Mood Disorder, Bipolar
Interventions
AssureRx GeneSight genotyping results, Treatment as usual
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 24, 2026, 4:58 PM EDT
Active, not recruiting Not applicable Interventional

CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs

NCT06565546
View directory record Official record
Conditions
Ventral Hernia
Interventions
Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin, Acetaminophen and Gabapentin: standard postoperative pain medications
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01225380
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01271790
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
85
States / cities
Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 24, 2026, 4:58 PM EDT
Not listed Not applicable Interventional

Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT

NCT02120729
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Genotype-guided care
Other
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Clopidogrel Monotherapy in Patients With High Bleeding Risk

NCT05223335
View directory record Official record
Conditions
Bleeding Complications
Interventions
Clopidogrel, Prasugrel, Tricagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 24, 2026, 4:58 PM EDT
Terminated No phase listed Observational

Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study

NCT00995514
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
4,471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 24, 2026, 4:58 PM EDT
Terminated No phase listed Observational

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

NCT01465516
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Boceprevir
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

NCT01643499
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Duct Cell Adenocarcinoma of the Pancreas, Intestinal Adenocarcinoma of the Stomach, Localized Unresectable Adult Primary Liver Cancer, Metastatic Carcinoma of Unknown Primary, Metastatic Extrahepatic Bile Duct Cancer, Mixed Adenocarcinoma of the Stomach, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Newly Diagnosed Carcinoma of Unknown Primary, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage III Pancreatic Cancer, Stage IIIA Colon Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Gastric Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Gastric Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Gastric Cancer, Stage IIIC Rectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colon Cancer, Stage IVA Gallbladder Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Gallbladder Cancer, Stage IVB Rectal Cancer, Unresectable Extrahepatic Bile Duct Cancer
Interventions
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery

NCT03943927
View directory record Official record
Conditions
Post-operative Atrial Fibrillation
Interventions
Guided Metoprolol Management
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 24, 2026, 4:58 PM EDT
Completed No phase listed Observational

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

NCT02345356
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Coagulopathies, Pulmonary Embolism
Interventions
Genotype-guided, Standard-of-Care
Genetic · Other
Lead sponsor
University of Puerto Rico
Other
Eligibility
21 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)

NCT00249405
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse
Interventions
Citalopram + MI, Placebo + MI
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients

NCT03020589
View directory record Official record
Conditions
Renal Transplant
Interventions
Tacrolimus
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 24, 2026, 4:58 PM EDT
Suspended Phase 4 Interventional

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

NCT02366819
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Stage IIB Gastric Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Gastric Cancer
Interventions
Oxaliplatin, Leucovorin Calcium, Irinotecan Hydrochloride, Fluorouracil, Conventional Surgery
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 24, 2026, 4:58 PM EDT
Terminated Not applicable Interventional

Genotype-guided Supportive Care in Symptom Treatment of Cancer Patients

NCT03924557
View directory record Official record
Conditions
Chemotherapy, Supportive Care, Genotyping
Interventions
Genotype-guided Supportive Care
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Oct 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention

NCT02508116
View directory record Official record
Conditions
Acute Coronary Syndrome, Cardiovascular Diseases
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 24, 2026, 4:58 PM EDT